Borrow R, Southern J, Andrews N, Peake N, Rahim R, Acuna M, Martin S, Miller E, Kaczmarski E
Meningococcal Reference Unit, Manchester Public Health Laboratory, Withington Hospital, Nell Lane, West Didsbury, M20 2LR, Manchester, UK.
Vaccine. 2001 Apr 30;19(23-24):3043-50. doi: 10.1016/s0264-410x(01)00050-0.
Few data are available on the kinetics of meningococcal serogroup C-specific antibody production following meningococcal serogroup C conjugate (MCC) vaccination, particularly in those who have received prior meningococcal A/C polysaccharide (MACP) vaccination(s). Laboratory staff who had previously received either one dose (n = 35), two doses (n = 18) of MACP vaccine or who were naïve to previous meningococcal vaccination (n = 42) were vaccinated with MCC. Bloods were taken pre-vaccination, on the subsequent 4 days and on days 10 and 28. Serogroup C serum bactericidal antibody (SBA), and anti-serogroup C-specific IgG, IgM and IgA were measured. There were no significant differences between the groups who had received either 2 or 1 prior dose(s) of MACP, therefore, these results were combined. Up to day 4 there was no evidence of a significant increase or decrease in the median levels of SBA, IgG, IgM or IgA in either the naïve or MACP groups, although about 20% of individuals did have 4-fold SBA rises by day 4. By day 10 there were large significant increases in the levels of SBA, IgG, IgM and IgA with respective fold increases from pre-vaccination levels of 4.6, 1.9, 1.2 and 2.1 in the MACP group and 270, 13.4, 4.8 and 33.8 in the naïve group. Further significant increases were seen between day 10 and 28 for SBA, IgG and IgM (naïve group only). By day 28, 4-fold SBA rises had occurred in 63.5% of the MACP group and 97.6% of the naïve group. The SBA GMT on day 28 significantly differed between the naïve and MACP groups with GMTs 2.8-fold higher in the naïve group (P = 0.021). In conclusion, no decline in serogroup C-specific antibody levels was demonstrated immediately post-MCC vaccination whilst these levels had risen significantly by day 10. Putative protective SBA titres (> or =8, 32 or 128) were observed by day 10 following MCC vaccination regardless of MACP history.
关于接种脑膜炎球菌C群结合疫苗(MCC)后脑膜炎球菌C群特异性抗体产生的动力学数据很少,尤其是在那些之前接种过脑膜炎球菌A/C多糖疫苗(MACP)的人群中。之前接种过一剂(n = 35)、两剂(n = 18)MACP疫苗或之前未接种过脑膜炎球菌疫苗(n = 42)的实验室工作人员接种了MCC。在接种前、随后4天以及第10天和第28天采集血液。检测C群血清杀菌抗体(SBA)以及抗C群特异性IgG、IgM和IgA。之前接种过2剂或1剂MACP的组之间没有显著差异,因此,将这些结果合并。到第4天,无论是未接种过疫苗组还是MACP组,SBA、IgG、IgM或IgA的中位数水平均没有显著升高或降低的证据,尽管约20%的个体在第4天时SBA升高了4倍。到第10天,MACP组的SBA、IgG、IgM和IgA水平大幅显著升高,相对于接种前水平的倍数增加分别为4.6、1.9、1.2和2.1,未接种过疫苗组分别为270、13.4、4.8和33.8。在第10天至28天之间,SBA、IgG和IgM(仅未接种过疫苗组)进一步显著升高。到第28天,MACP组63.5%的个体和未接种过疫苗组97.6%的个体SBA升高了4倍。第28天未接种过疫苗组和MACP组的SBA几何平均滴度(GMT)有显著差异,未接种过疫苗组的GMT高2.8倍(P = 0.021)。总之,接种MCC疫苗后立即未显示C群特异性抗体水平下降,而到第10天时这些水平已显著升高。无论MACP接种史如何,接种MCC疫苗后第10天观察到了推定的保护性SBA滴度(≥8、32或128)。